Merus Announces Potential Pricing for IPO
Merus plans to offer more than 4 million shares within an expected price range of $14 to $16 per share in an initial public offering valued up to more than $79 million.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Merus has filed an amended F-1 form with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO). The company plans to offer 4.33 million shares within the expected price range of $14 to $16 per share with an overallotment option for an additional 650,000 shares. The entire offering at the maximum price is valued up to $79.73 million. The company intends to list on the Nasdaq Global Market under the symbol MRUS.
The underwriters for the offering are Citigroup, Guggenheim Securities, Jefferies and Wedbush PacGrow.
This clinical-stage immuno-oncology company is developing innovative bispecific antibody therapeutics. The pipeline of full-length human bispecific antibody candidates (Biclonics) are generated from the technology platform. By binding to two different antigens, or targets, Biclonics can be designed to simultaneously block receptors that drive tumor cell growth and survival and to mobilize the patient’s immune response by activating various killer cells to eradicate tumors.
In preclinical studies, the bispecific antibody candidates were effective in killing tumor cells, a result that the company believes supports its potential efficacy in the treatment of cancer. In February 2015, Merus commenced a Phase 1/2 clinical trial of the lead bispecific antibody candidate, MCLA-128, for the treatment of HER2-expressing solid tumors, and it expects to report top-line results from this trial by the first half of 2017.
[nativounit]
In the second quarter of 2016, Merus expects to commence a Phase 1/2 clinical trial with its second bispecific antibody candidate, MCLA-117, for the treatment of acute myeloid leukemia. Additionally, Merus has several bispecific antibody candidates in preclinical development that bind to combinations of immunomodulatory molecules, including programmed death receptor-1, or PD-1, and programmed death-ligand 1, or PD-L1, both of which are believed to play a significant role in treating cancer.
The company intends to use the net proceeds from this offering to further develop its pipeline and to fund its clinical studies. The remainder will be used for working capital and general corporate purposes.
Contact [email protected] for any questions or corrections.
Chris Lange is a financial and geopolitical writer with more than a decade of experience covering a myriad of topics. He has published thousands of articles for 24/7 Wall St., with past coverage focused heavily on stocks, IPOs, healthcare, defense, global affairs, and technology.
His work has been quoted, or referenced by a number of outlets including Business Insider, USA Today, Yahoo Finance, MSN, The Motley Fool, and many other publications. A graduate of Southwestern University, he studied business with a focus on investments and has previous experience in banking and startups.
When not reading or writing the news, he is following his passion for Lacrosse, playing chess, or building solar projects with his dad.
